20240021315. IN VITRO METHOD FOR PREDICTING THE RISK OF DEVELOPING A BREAST LATE EFFECT AFTER RADIOTHERAPY simplified abstract (INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER)

From WikiPatents
Jump to navigation Jump to search

IN VITRO METHOD FOR PREDICTING THE RISK OF DEVELOPING A BREAST LATE EFFECT AFTER RADIOTHERAPY

Organization Name

INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER

Inventor(s)

David Azria of Fontanes (FR)

Sophie Gourgou of Jacou (FR)

IN VITRO METHOD FOR PREDICTING THE RISK OF DEVELOPING A BREAST LATE EFFECT AFTER RADIOTHERAPY - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240021315 titled 'IN VITRO METHOD FOR PREDICTING THE RISK OF DEVELOPING A BREAST LATE EFFECT AFTER RADIOTHERAPY

Simplified Explanation

The present invention is a new diagnosis method and calculator for predicting the risk of developing a breast late effect (BLE) in a subject after radiotherapy (RT). The BLE is defined as atrophic skin, telangiectasia, induration (fibrosis), necrosis or ulceration. The method uses radiation-induced late effect using T-lymphocyte apoptosis (RILA) and clinical parameters. The invention also includes diagnosis kits for implementing the method and a nomogram.

  • The invention is a new diagnosis method and calculator for predicting the risk of developing a breast late effect (BLE) after radiotherapy (RT).
  • The BLE is defined as atrophic skin, telangiectasia, induration (fibrosis), necrosis or ulceration.
  • The method uses radiation-induced late effect using T-lymphocyte apoptosis (RILA) and clinical parameters.
  • The invention includes diagnosis kits for implementing the method.
  • The invention also includes a nomogram.

Potential applications of this technology:

  • Predicting the risk of developing a breast late effect (BLE) in patients who have undergone radiotherapy.
  • Assisting healthcare professionals in determining the appropriate treatment plan for patients based on their risk of developing a BLE.
  • Improving patient outcomes by identifying individuals who are at a higher risk of developing a BLE and providing them with targeted interventions or preventive measures.

Problems solved by this technology:

  • Currently, there is no reliable method for predicting the risk of developing a breast late effect (BLE) after radiotherapy.
  • Healthcare professionals often have to rely on subjective assessments and clinical observations to determine the risk of BLE, which can be inaccurate and inconsistent.
  • This technology provides a more objective and accurate method for assessing the risk of BLE, allowing for better patient management and personalized treatment plans.

Benefits of this technology:

  • Enables early identification of individuals at a higher risk of developing a breast late effect (BLE) after radiotherapy.
  • Facilitates targeted interventions and preventive measures to reduce the risk of BLE and improve patient outcomes.
  • Provides healthcare professionals with a more objective and reliable tool for assessing the risk of BLE, leading to better treatment planning and decision-making.


Original Abstract Submitted

the present invention is drawn to a new diagnosis method and a calculator for predicting the risk of developing a breast late effect (ble), which is defined as atrophic skin, telangiectasia, induration (fibrosis), necrosis or ulceration, in a subject after radiotherapy (rt), by using radiation induced late effect using t-lymphocyte apoptosis (rila) and clinical parameters. the invention is also drawn to diagnosis kits for the implementation of the method and a nomogram.

Retrieved from "http://wikipatents.org/index.php?title=20240021315._IN_VITRO_METHOD_FOR_PREDICTING_THE_RISK_OF_DEVELOPING_A_BREAST_LATE_EFFECT_AFTER_RADIOTHERAPY_simplified_abstract_(INSTITUT_RÉGIONAL_DU_CANCER_DE_MONTPELLIER)&oldid=28668"